Label Changes for:
Dyazide (hydrochlorothiazide/triamterene) capsules
Changes have been made to the ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – February 2010
- Erythema multiforme including Steven-Johnson syndrome, exfoliative dermatitis, including toxic epidermal necrolysis